Myocardial Fibrosis Assessment in Hypertensive Individuals with Chronic Kidney Disease
Location
Science Center: Bent Corridor
Document Type
Poster - Open Access
Start Date
4-28-2023 12:00 PM
End Date
4-28-2023 2:00 PM
Abstract
Background:
Chronic kidney disease (CKD) is associated with an increased risk of myocardial fibrosis which is a substrate for arrhythmia and heart failure. Myocardial fibrosis can be assessed non-invasively by cardiac magnetic resonance (CMR) T1 mapping or by circulating biomarkers; however, the performance of such biomarkers in the setting of impaired kidney function has not been rigorously tested.
Methods:
The Systolic Blood Pressure Intervention Trial (SPRINT) enrolled 9,361 US participants aged ≥50 years, at increased cardiovascular risk, and randomized them to intensive (<120mmHg) or standard (<140mmHg) systolic blood pressure lowering. A subgroup of 337 SPRINT participants with and without CKD had CMR T1 mapping, and measured plasma biomarkers of myocardial fibrosis: C-terminal propeptide of procollagen type I (CICP), N-terminal propeptide of procollagen type 3 (P3NP), and Galectin 3 (Gal-3) at study baseline.
Results:
Study participants had a mean age of 64.3 [SD 8.9] years, 44.8% were women, and 21% had CKD. The levels of Gal-3, PICP, and PIIINP were found inversely correlated with estimated glomerular filtration rate (eGFR) and positively correlated with log-transformed spot albumin/creatinine (p-value < 0.001 for all). No correlation was found between the level of the three biomarkers and the CMR T1 times, a more precise measure of myocardial fibrosis.
Conclusion:
In individuals with and without CKD, Gal-3, PICP, and PIIINP levels were not associated with CMR T1 times. Elevated plasma biomarkers level in the context of CKD should be interpreted with caution as it may reflect their decreased urinary clearance, rather than true pathologic processes.
Keywords:
Nephrology, Myocardial fibrosis, Biomarkers
Recommended Citation
Wilkerson, Jasmine G. and Dobre, Mirela MD, "Myocardial Fibrosis Assessment in Hypertensive Individuals with Chronic Kidney Disease" (2023). Research Symposium. 12.
https://digitalcommons.oberlin.edu/researchsymp/2023/posters/12
Major
Biology
Project Mentor(s)
Dr. Monica Mantano, Department of Medicine, Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center
Dr. Mirela Dobre, Department of Medicine, Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center
2023
Myocardial Fibrosis Assessment in Hypertensive Individuals with Chronic Kidney Disease
Science Center: Bent Corridor
Background:
Chronic kidney disease (CKD) is associated with an increased risk of myocardial fibrosis which is a substrate for arrhythmia and heart failure. Myocardial fibrosis can be assessed non-invasively by cardiac magnetic resonance (CMR) T1 mapping or by circulating biomarkers; however, the performance of such biomarkers in the setting of impaired kidney function has not been rigorously tested.
Methods:
The Systolic Blood Pressure Intervention Trial (SPRINT) enrolled 9,361 US participants aged ≥50 years, at increased cardiovascular risk, and randomized them to intensive (<120mmHg) or standard (<140mmHg) systolic blood pressure lowering. A subgroup of 337 SPRINT participants with and without CKD had CMR T1 mapping, and measured plasma biomarkers of myocardial fibrosis: C-terminal propeptide of procollagen type I (CICP), N-terminal propeptide of procollagen type 3 (P3NP), and Galectin 3 (Gal-3) at study baseline.
Results:
Study participants had a mean age of 64.3 [SD 8.9] years, 44.8% were women, and 21% had CKD. The levels of Gal-3, PICP, and PIIINP were found inversely correlated with estimated glomerular filtration rate (eGFR) and positively correlated with log-transformed spot albumin/creatinine (p-value < 0.001 for all). No correlation was found between the level of the three biomarkers and the CMR T1 times, a more precise measure of myocardial fibrosis.
Conclusion:
In individuals with and without CKD, Gal-3, PICP, and PIIINP levels were not associated with CMR T1 times. Elevated plasma biomarkers level in the context of CKD should be interpreted with caution as it may reflect their decreased urinary clearance, rather than true pathologic processes.
